Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
1 study found for:    NCT01691898
Show Display Options
Rank Status Study
1 Recruiting A Safety and Efficacy Study of Pinatuzumab Vedotin (DCDT2980S) Combined With Rituximab (MabThera/Rituxan) or Polatuzumab Vedotin (DCDS4501A) Combined With Rituximab and Polatuzumab Vedotin Combined With Obinutuzumab in Participants With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (ROMULUS)
Condition: Diffuse Large B-Cell Lymphoma, Lymphoma, Follicular
Interventions: Drug: Obinutuzumab;   Drug: Pinatuzumab Vedotin;   Drug: Polatuzumab Vedotin;   Drug: Rituximab

Study has passed its completion date and status has not been verified in more than two years.